After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

When adventurers talk about Mount Everest, most often it's about climbing the world's highest peak. In October, Jim Morrison became the first person to ski down Everest’s most dangerous route. The ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Six friends enter a cave system looking for a spelunking adventure, but the creatures that await them are hungry for blood. Jen Karner has spent the last 10 years covering technology, streaming ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Dr. James McCaffrey presents a complete end-to-end demonstration of the kernel ridge regression technique to predict a single numeric value. The demo uses stochastic gradient descent, one of two ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...